Bellmunt risk score enables survival prediction in men with metastatic castration resistant prostate cancer (mCRPC) undergoing PSMA-targeted radioligand therapy (LUMEN).

ABSTRACT:

Purpose

[¹⁷⁷Lu]Lu-PSMA-617 therapy has emerged as a promising radioligand treatment for metastatic castration-resistant prostate cancer (mCRPC). Given the overall poor prognosis of mCRPC, accurately predicting the key endpoint overall survival (OS) remains an ongoing challenge, crucial for optimizing risk/benefit assessment prior to treatment. This study investigates the prognostic utility of the simple designed Bellmunt Risk Score (BRS) in mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617.

Methods

We retrospectively evaluated data from 386 mCRPC patients who had received [¹⁷⁷Lu]Lu-PSMA-617 therapy at our center. BRS was constructed by attributing one point for each of the following risk factors: ECOG performance status (ECOG PS) > 0, hemoglobin

SUBMITTER: Buttner T 

PROVIDER: S-EPMC12830477 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature